5‐YEAR (Y) FOLLOW‐UP OF A PHASE 2 STUDY OF IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER CLL PATIENTS (PTS).

Autor:	Ahn, I. E., Brander, D. M., Ren, Y., Zhou, Y., Tyekucheva, S., Walker, H. A., Black, R., Montegaard, J., Alencar, A., Shune, L., Omaira, M., Jacobson, C. A., Armand, P., Ng, S., Crombie, J., Fisher, D. C., LaCasce, A. S., Arnason, J., Hochberg, E. P., Takvorian, R. W.
Předmět:	CHRONIC lymphocytic leukemia RITUXIMAB SKIN cancer CYCLOPHOSPHAMIDE FLUDARABINE
Zdroj:	Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p231-233, 3p
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text